Laia Barrachina-Bonet
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Laia Barrachina-Bonet has a total of 74 co-authors. Here are the top co-authors by number of shared publications:
- Clara Cavero-Carbonell
Affiliation Rare Diseases Research Unit, Foundation for the Promotion of Health and Biomedical Research in the Valencian Region, Valencia, Spain
6 shared publications - Laura García-Villodre
Área de Investigación Enfermedades Raras. Fundación para el Fomento de la Investigación Sanitaria y Biomédica de la Comunitat Valenciana (Fundació FISABIO). Valencia. España
4 shared publications Clara Cavero-Carbonell
Foundation for the Promotion of Health and Bio-medical Research in the Valencian Region, Valencia, Spain
3 shared publications- Joan K. Morris
School of Health and Medical Sciences, City St George’s, University of London, London, UK
3 shared publications - Lucía Páramo-Rodríguez
Área de Investigación Enfermedades Raras. Fundación para el Fomento de la Investigación Sanitaria y Biomédica de la Comunitat Valenciana (Fundació FISABIO). Valencia. España. / Unidad Mixta de Investigación en Enfermedades Raras. Fundación para el Fomento de la Investigación Sanitaria y Biomédica de la Comunitat Valenciana-Universitat de València (FISABIO-UVEG). Valencia. España
3 shared publications - Oscar Zurriaga
University of Valencia
3 shared publications
Latest Publications
- Open Access
- 29 October 2026
- Published by Ministerio de Sanidad del Gobierno de España in Revista Espanola de Salud Publica
- Vol. 100
Anomalías congénitas del sistema nervioso en menores de un año en la Comunitat Valenciana. Un estudio epidemiológico descriptivo (2007-2022)
FUNDAMENTOS // Las anomalías congénitas y, en concreto, las del sistema nervioso (ACSN) son un importante problema de Salud Pública y contribuyen a una alta mortalidad perinatal e infantil. El objetivo de este trabajo fue determinar y describir la tendencia y distribución de las ACSN en la Comunitat Valenciana, en menores de un año, durante el periodo 2007-2022. MÉTODOS // Se realizó un estudio transversal. Se seleccionaron los nacidos vivos, nacidos muertos e interrupciones voluntarias del embarazo del Registro poblacional de anomalías congénitas de la Comunitat Valenciana con ACSN entre 2007-2022. Se describieron las variables de estudio, se calculó la prevalencia según metodología EUROCAT por cada 10.000 nacimientos (incluyendo nacidos vivos y muertos) y la probabilidad de supervivencia en los nacidos vivos con el método Kaplan-Meyer. El análisis estadístico fue realizado mediante Excel y el software IBM SPSS Statistics 23. RESULTADOS // Se identificaron 1.862 casos, con una prevalencia de 26,1 por cada 10.000 nacimientos. Predominaron los nacidos vivos (54,6%) y la Hidrocefalia fue el subgrupo de malformaciones de ACSN más frecuente (20,7%). La probabilidad de supervivencia fue del 94,9%, identificando diferencias entre subgrupos de ACSN. Respecto a las gestantes, la edad media fue de 31,9 años y el país de nacimiento mayoritario fue España (69,1%). La mayor prevalencia de casos con ACSN se identificó en las gestantes menores de veinte años (38,4 por cada 10.000 nacimientos) y en las residentes en la provincia de Castellón (34,1 por cada 10.000 nacimientos). CONCLUSIONES // La prevalencia de casos con ACSN es similar a la de la red de registros europeos de anomalías congénitas. Identificar mayor prevalencia de casos en las embarazadas más jóvenes o en las residentes en Castellón podría estar relacionado con la mayor proporción de gestantes procedentes de determinados países presentes en esa provincia.
- 29 October 2026
- Published by Ministerio de Sanidad del Gobierno de España in Revista Espanola de Salud Publica
- Vol. 100
Open AccessAnomalías congénitas del sistema nervioso en menores de un año en la Comunitat Valenciana. Un estudio epidemiológico descriptivo (2007-2022)
FUNDAMENTOS // Las anomalías congénitas y, en concreto, las del sistema nervioso (ACSN) son un importante problema de Salud Pública y contribuyen a una alta mortalidad perinatal e infantil. El objetivo de este trabajo fue determinar y describir la tendencia y distribución de las ACSN en la Comunitat Valenciana, en menores de un año, durante el periodo 2007-2022. MÉTODOS // Se realizó un estudio transversal. Se seleccionaron los nacidos vivos, nacidos muertos e interrupciones voluntarias del embarazo del Registro poblacional de anomalías congénitas de la Comunitat Valenciana con ACSN entre 2007-2022. Se describieron las variables de estudio, se calculó la prevalencia según metodología EUROCAT por cada 10.000 nacimientos (incluyendo nacidos vivos y muertos) y la probabilidad de supervivencia en los nacidos vivos con el método Kaplan-Meyer. El análisis estadístico fue realizado mediante Excel y el software IBM SPSS Statistics 23. RESULTADOS // Se identificaron 1.862 casos, con una prevalencia de 26,1 por cada 10.000 nacimientos. Predominaron los nacidos vivos (54,6%) y la Hidrocefalia fue el subgrupo de malformaciones de ACSN más frecuente (20,7%). La probabilidad de supervivencia fue del 94,9%, identificando diferencias entre subgrupos de ACSN. Respecto a las gestantes, la edad media fue de 31,9 años y el país de nacimiento mayoritario fue España (69,1%). La mayor prevalencia de casos con ACSN se identificó en las gestantes menores de veinte años (38,4 por cada 10.000 nacimientos) y en las residentes en la provincia de Castellón (34,1 por cada 10.000 nacimientos). CONCLUSIONES // La prevalencia de casos con ACSN es similar a la de la red de registros europeos de anomalías congénitas. Identificar mayor prevalencia de casos en las embarazadas más jóvenes o en las residentes en Castellón podría estar relacionado con la mayor proporción de gestantes procedentes de determinados países presentes en esa provincia.
- Open Access
- 6 November 2025
- Published by MDPI AG in Current Oncology
- Vol. 32 (11) , 621
Risk of Childhood Cancer in Children with Congenital Anomalies and Their Impact on Survival: A Population-Based Registry Approach
Despite advances in treatment, childhood cancer survivors continue to experience substantial comorbidities stemming from chronic health conditions and face an elevated risk of premature mortality compared to the general population
- 6 November 2025
- Published by MDPI AG in Current Oncology
- Vol. 32 (11) , 621
Open AccessRisk of Childhood Cancer in Children with Congenital Anomalies and Their Impact on Survival: A Population-Based Registry Approach
Despite advances in treatment, childhood cancer survivors continue to experience substantial comorbidities stemming from chronic health conditions and face an elevated risk of premature mortality compared to the general population
- Open Access
Identification of gestational diabetes mellitus in European electronic healthcare databases: insights from the ConcePTION project
Objective: To develop and compare algorithms for identifying gestational diabetes mellitus (GDM) across European electronic healthcare databases and evaluate their impact on the estimated prevalence. Design: Multi-national cohort study using routinely collected electronic healthcare data Setting: National and regional databases in five European countries (Norway, Finland, Italy, Spain and France), in primary and/or secondary care. Participants: Pregnancy cohorts resulting in stillbirths or live births between 2009 and 2020, comprising 602 897 pregnancies in Norway, 507 904 in Finland, 374 009 in Italy, 193 495 in Spain and 116 762 in France. Primary and secondary outcomes: The primary outcome was the prevalence of GDM identified using six algorithms: (1) Only diagnosis; (2) Diagnosis or prescription; (3) Two diagnoses or prescriptions ( 2DxRx ); (4) Diagnosis including unspecified diabetes in pregnancy or prescription ( DxRx broad ); (5) Diagnosis excluding pre-existing diabetes in pregnancy or prescription; (6) Registration of GDM in a birth registry ( BR ). Results: The strictest algorithm ( 2DxRx ) resulted in the lowest GDM prevalence, while the broadest ( DxRx broad ) resulted in the highest, except in France where it was BR . In the Nordic countries, GDM prevalence varied only slightly by algorithm; greater variations were observed in other countries. The prevalence ranged from 3.5% (95% CI: 3.5% to 3.5%) to 4.6% (95% CI: 4.5% to 4.7%) in Norway; 12.1% (95% CI: 12.0% to 12.2%) to 15.8% (95% CI: 15.7% to 15.9%) in Finland, where prevalence was much higher than elsewhere. The prevalence ranged from 1.3% (95% CI: 1.3% to 1.3%) to 5.4% (95% CI: 5.3% to 5.5%) in Italy; 1.6% (95% CI: 1.5% to 1.7%) to 6.2% (95% CI: 6.1% to 6.3%) in Spain; and 1.7% (95% CI: 1.6% to 1.8%) to 5.8% (95% CI: 5.7% to 5.9%) in France. Conclusions: In this multinational study, GDM prevalence ranged from 1.3% to 15.8% depending on the algorithm and database. Nordic countries showed smaller differences in prevalence between algorithms, while the other countries showed larger variations, likely due to differences in coding practices, healthcare systems and database coverage.
Open AccessIdentification of gestational diabetes mellitus in European electronic healthcare databases: insights from the ConcePTION project
Objective: To develop and compare algorithms for identifying gestational diabetes mellitus (GDM) across European electronic healthcare databases and evaluate their impact on the estimated prevalence. Design: Multi-national cohort study using routinely collected electronic healthcare data Setting: National and regional databases in five European countries (Norway, Finland, Italy, Spain and France), in primary and/or secondary care. Participants: Pregnancy cohorts resulting in stillbirths or live births between 2009 and 2020, comprising 602 897 pregnancies in Norway, 507 904 in Finland, 374 009 in Italy, 193 495 in Spain and 116 762 in France. Primary and secondary outcomes: The primary outcome was the prevalence of GDM identified using six algorithms: (1) Only diagnosis; (2) Diagnosis or prescription; (3) Two diagnoses or prescriptions ( 2DxRx ); (4) Diagnosis including unspecified diabetes in pregnancy or prescription ( DxRx broad ); (5) Diagnosis excluding pre-existing diabetes in pregnancy or prescription; (6) Registration of GDM in a birth registry ( BR ). Results: The strictest algorithm ( 2DxRx ) resulted in the lowest GDM prevalence, while the broadest ( DxRx broad ) resulted in the highest, except in France where it was BR . In the Nordic countries, GDM prevalence varied only slightly by algorithm; greater variations were observed in other countries. The prevalence ranged from 3.5% (95% CI: 3.5% to 3.5%) to 4.6% (95% CI: 4.5% to 4.7%) in Norway; 12.1% (95% CI: 12.0% to 12.2%) to 15.8% (95% CI: 15.7% to 15.9%) in Finland, where prevalence was much higher than elsewhere. The prevalence ranged from 1.3% (95% CI: 1.3% to 1.3%) to 5.4% (95% CI: 5.3% to 5.5%) in Italy; 1.6% (95% CI: 1.5% to 1.7%) to 6.2% (95% CI: 6.1% to 6.3%) in Spain; and 1.7% (95% CI: 1.6% to 1.8%) to 5.8% (95% CI: 5.7% to 5.9%) in France. Conclusions: In this multinational study, GDM prevalence ranged from 1.3% to 15.8% depending on the algorithm and database. Nordic countries showed smaller differences in prevalence between algorithms, while the other countries showed larger variations, likely due to differences in coding practices, healthcare systems and database coverage.
- 9 July 2025
- Vol. 39, 102509
[Pregnant women profile with children with congenital anomalies in Valencian Region].
To describe pregnant women's profile with children with congenital defects (CD) in Valencian Region and to identify differences in pregnancy outcomes based on the characteristics of pregnant. Cross-sectional epidemiological study. Pregnant women with live births or stillbirths between 2007-2021 were selected from the CD population-based registry of Valencian Region. Pregnant women were classified by: age (2 test were used. CD prevalence (total and by groups) and its 95% confidence intervals per 10,000 births were calculated for the three characteristics. 12,306 pregnant women were identified. 65.0% were <35 years, 72.9% born in Spain and 45.7% resided in Valencia province. The highest prevalence of CD children with statistically significant differences was in woman pregnant ≥35 years (194.7/10,000 births), not born in Spain (195.9/10,000 births) and residents in Castellon (245.2/10,000 births). The study highlights the relationship between CD and age, residence, and birth country of pregnant women, and confirmed the CD surveillance is a Public Health challenge.
- 9 July 2025
- Vol. 39, 102509
[Pregnant women profile with children with congenital anomalies in Valencian Region].
To describe pregnant women's profile with children with congenital defects (CD) in Valencian Region and to identify differences in pregnancy outcomes based on the characteristics of pregnant. Cross-sectional epidemiological study. Pregnant women with live births or stillbirths between 2007-2021 were selected from the CD population-based registry of Valencian Region. Pregnant women were classified by: age (2 test were used. CD prevalence (total and by groups) and its 95% confidence intervals per 10,000 births were calculated for the three characteristics. 12,306 pregnant women were identified. 65.0% were <35 years, 72.9% born in Spain and 45.7% resided in Valencia province. The highest prevalence of CD children with statistically significant differences was in woman pregnant ≥35 years (194.7/10,000 births), not born in Spain (195.9/10,000 births) and residents in Castellon (245.2/10,000 births). The study highlights the relationship between CD and age, residence, and birth country of pregnant women, and confirmed the CD surveillance is a Public Health challenge.
- 15 November 2023
- Vol. 97
[Prevalencia de la Telangiectasia Hemorrágica Hereditaria: estudio de base poblacional en la Comunitat Valenciana (España).].
The Hereditary Haemorrhagic Telangiectasia (HHT) is a low prevalence disease which presents heterogeneous signs and symptoms and just few population-based epidemiological studies are available. The aims of this paper were to describe the sociodemographic characteristics of people affected by HHT in the Valencian Region (VR), to determine its prevalence and mortality rate, and to analyse the sources of recruitment and verification tests used by the Rare Diseases Information System of the VR (SIER-CV). Cross-sectional observational epidemiological study of HHT prevalent cases between 2010-2019 in SIER-CV was performed. The distribution of sociodemographic and clinical characteristics were determined, the prevalence and mortality rates, and the sources of recruitment and verification tests used by SIER-CV were analysed. Statistical analysis was performed using Stata (version 16.1) and Microsoft Excel Office. During 2010-2019, two hundred cases were identified, 55.5% were female. The mean ages were: 56.8 years at recruitment and 50.9 years at diagnosis. 48.4% of cases were diagnosed between thirty-six/sixty-four years of age. 25.5% died, with a mean age of 76.6 years, identifying statistically significant differences above the age of 64. The prevalence was 39.6/1,000,000 inhabitants and the crude mortality rate was 10.1/1,000,000 inhabitants. 95.5% of cases were recruited from the Hospital discharges database and the most frequent verification test was the clinical basis (45.7%). The increasing trend in prevalence coincides with a better knowledge of HHT, which favours its detection, and also with dying at older ages. To describe the situation of HHT in the VR facilitates its health management and contributes to the establishment of the relevant health policies for the HHT. The need to promote genetic diagnosis and to incorporate the Primary Care Clinical History as a source of recruitment in the population-based registries has been shown.
- 15 November 2023
- Vol. 97
[Prevalencia de la Telangiectasia Hemorrágica Hereditaria: estudio de base poblacional en la Comunitat Valenciana (España).].
The Hereditary Haemorrhagic Telangiectasia (HHT) is a low prevalence disease which presents heterogeneous signs and symptoms and just few population-based epidemiological studies are available. The aims of this paper were to describe the sociodemographic characteristics of people affected by HHT in the Valencian Region (VR), to determine its prevalence and mortality rate, and to analyse the sources of recruitment and verification tests used by the Rare Diseases Information System of the VR (SIER-CV). Cross-sectional observational epidemiological study of HHT prevalent cases between 2010-2019 in SIER-CV was performed. The distribution of sociodemographic and clinical characteristics were determined, the prevalence and mortality rates, and the sources of recruitment and verification tests used by SIER-CV were analysed. Statistical analysis was performed using Stata (version 16.1) and Microsoft Excel Office. During 2010-2019, two hundred cases were identified, 55.5% were female. The mean ages were: 56.8 years at recruitment and 50.9 years at diagnosis. 48.4% of cases were diagnosed between thirty-six/sixty-four years of age. 25.5% died, with a mean age of 76.6 years, identifying statistically significant differences above the age of 64. The prevalence was 39.6/1,000,000 inhabitants and the crude mortality rate was 10.1/1,000,000 inhabitants. 95.5% of cases were recruited from the Hospital discharges database and the most frequent verification test was the clinical basis (45.7%). The increasing trend in prevalence coincides with a better knowledge of HHT, which favours its detection, and also with dying at older ages. To describe the situation of HHT in the VR facilitates its health management and contributes to the establishment of the relevant health policies for the HHT. The need to promote genetic diagnosis and to incorporate the Primary Care Clinical History as a source of recruitment in the population-based registries has been shown.
- Open Access
- 30 August 2023
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 18 (8) , e0290711
Creating a population-based cohort of children born with and without congenital anomalies using birth data matched to hospital discharge databases in 11 European regions: Assessment of linkage success and data quality
Linking routinely collected healthcare administrative data is a valuable method for conducting research on morbidity outcomes, but linkage quality and accuracy needs to be assessed for bias as the data were not collected for research. The aim of this study was to describe the rates of linking data on children with and without congenital anomalies to regional or national hospital discharge databases and to evaluate the quality of the matched data. Eleven population-based EUROCAT registries participated in a EUROlinkCAT study linking data on children with a congenital anomaly and children without congenital anomalies (reference children) born between 1995 and 2014 to administrative databases including hospital discharge records. Odds ratios (OR), adjusted by region, were estimated to assess the association of maternal and child characteristics on the likelihood of being matched. Data on 102,654 children with congenital anomalies were extracted from 11 EUROCAT registries and 2,199,379 reference children from birth registers in seven regions. Overall, 97% of children with congenital anomalies and 95% of reference children were successfully matched to administrative databases. Information on maternal age, multiple birth status, sex, gestational age and birthweight were >95% complete in the linked datasets for most regions. Compared with children born at term, those born at ≤27 weeks and 28–31 weeks were less likely to be matched (adjusted OR 0.23, 95% CI 0.21–0.25 and adjusted OR 0.75, 95% CI 0.70–0.81 respectively). For children born 32–36 weeks, those with congenital anomalies were less likely to be matched (adjusted OR 0.78, 95% CI 0.71–0.85) while reference children were more likely to be matched (adjusted OR 1.28, 95% CI 1.24–1.32). Children born to teenage mothers and mothers ≥35 years were less likely to be matched compared with mothers aged 20–34 years (adjusted ORs 0.92, 95% CI 0.88–0.96; and 0.87, 95% CI 0.86–0.89 respectively). The accuracy of linkage and the quality of the matched data suggest that these data are suitable for researching morbidity outcomes in most regions/countries. However, children born preterm and those born to mothers aged <20 and ≥35 years are less likely to be matched. While linkage to administrative databases enables identification of a reference group and long-term outcomes to be investigated, efforts are needed to improve linkages to population groups that are less likely to be linked.
- 30 August 2023
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 18 (8) , e0290711
Open AccessCreating a population-based cohort of children born with and without congenital anomalies using birth data matched to hospital discharge databases in 11 European regions: Assessment of linkage success and data quality
Linking routinely collected healthcare administrative data is a valuable method for conducting research on morbidity outcomes, but linkage quality and accuracy needs to be assessed for bias as the data were not collected for research. The aim of this study was to describe the rates of linking data on children with and without congenital anomalies to regional or national hospital discharge databases and to evaluate the quality of the matched data. Eleven population-based EUROCAT registries participated in a EUROlinkCAT study linking data on children with a congenital anomaly and children without congenital anomalies (reference children) born between 1995 and 2014 to administrative databases including hospital discharge records. Odds ratios (OR), adjusted by region, were estimated to assess the association of maternal and child characteristics on the likelihood of being matched. Data on 102,654 children with congenital anomalies were extracted from 11 EUROCAT registries and 2,199,379 reference children from birth registers in seven regions. Overall, 97% of children with congenital anomalies and 95% of reference children were successfully matched to administrative databases. Information on maternal age, multiple birth status, sex, gestational age and birthweight were >95% complete in the linked datasets for most regions. Compared with children born at term, those born at ≤27 weeks and 28–31 weeks were less likely to be matched (adjusted OR 0.23, 95% CI 0.21–0.25 and adjusted OR 0.75, 95% CI 0.70–0.81 respectively). For children born 32–36 weeks, those with congenital anomalies were less likely to be matched (adjusted OR 0.78, 95% CI 0.71–0.85) while reference children were more likely to be matched (adjusted OR 1.28, 95% CI 1.24–1.32). Children born to teenage mothers and mothers ≥35 years were less likely to be matched compared with mothers aged 20–34 years (adjusted ORs 0.92, 95% CI 0.88–0.96; and 0.87, 95% CI 0.86–0.89 respectively). The accuracy of linkage and the quality of the matched data suggest that these data are suitable for researching morbidity outcomes in most regions/countries. However, children born preterm and those born to mothers aged <20 and ≥35 years are less likely to be matched. While linkage to administrative databases enables identification of a reference group and long-term outcomes to be investigated, efforts are needed to improve linkages to population groups that are less likely to be linked.
- Open Access
- 4 March 2023
- Published by Springer Nature in European Journal of Pediatrics
- Vol. 182 (5) , 2235-2244
Prescriptions for insulin and insulin analogues in children with and without major congenital anomalies: a data linkage cohort study across six European regions
Are children with major congenital anomalies more likely to develop diabetes requiring insulin therapy, as indicated by prescriptions for insulin, than children without congenital anomalies? The aim of this study is to evaluate prescription rates of insulin/insulin analogues in children aged 0–9 years with and without major congenital anomalies. A EUROlinkCAT data linkage cohort study, involving six population-based congenital anomaly registries in five countries. Data on children with major congenital anomalies (60,662) and children without congenital anomalies (1,722,912), the reference group, were linked to prescription records. Birth cohort and gestational age were examined. The mean follow-up for all children was 6.2 years. In children with congenital anomalies aged 0–3 years, 0.04 per 100 child-years (95% CIs 0.01–0.07) had > 1 prescription for insulin/insulin analogues compared with 0.03 (95% CIs 0.01–0.06) in reference children, increasing ten-fold by age 8–9 years. The risk of > 1 prescription for insulin/insulin analogues aged 0–9 years in children with non-chromosomal anomalies (RR 0.92, 95% CI 0.84–1.00) was similar to that of reference children. However, children with chromosomal anomalies (RR 2.37, 95% CI 1.91–2.96), and specifically children with Down syndrome (RR 3.44, 95% CIs 2.70–4.37), Down syndrome with congenital heart defects (RR 3.86, 95% CIs 2.88–5.16) and Down syndrome without congenital heart defects (RR 2.78, 95% CIs 1.82–4.27), had a significantly increased risk of > 1 prescription for insulin/insulin analogues aged 0–9 years compared to reference children. Female children had a reduced risk of > 1 prescription aged 0–9 years compared with male children (RR 0.76, 95% CI 0.64–0.90 for children with congenital anomalies and RR 0.90, 95% CI 0.87–0.93 for reference children). Children without congenital anomalies born preterm (< 37 weeks) were more likely to have > 1 insulin/insulin analogue prescription compared to term births (RR 1.28, 95% CIs 1.20–1.36).Conclusion: This is the first population-based study using a standardised methodology across multiple countries. Males, children without congenital anomalies born preterm and those with chromosomal anomalies had an increased risk of being prescribed insulin/insulin analogues. These results will help clinicians to identify which congenital anomalies are associated with an increased risk of developing diabetes requiring insulin therapy and allow them to reassure families of children who have non-chromosomal anomalies that their risk is similar to that of the general population. What is Known:• Children and young adults with Down syndrome have an increased risk of diabetes requiring insulin therapy.• Children born prematurely have an increased risk of developing diabetes requiring insulin therapy. What is New:• Children with non-chromosomal anomalies do not have an increased risk of developing diabetes requiring insulin therapy compared to children without congenital anomalies.• Female children, with or without major congenital anomalies, are less likely to develop diabetes requiring insulin therapy before the age of 10 compared to male children.
- 4 March 2023
- Published by Springer Nature in European Journal of Pediatrics
- Vol. 182 (5) , 2235-2244
Open AccessPrescriptions for insulin and insulin analogues in children with and without major congenital anomalies: a data linkage cohort study across six European regions
Are children with major congenital anomalies more likely to develop diabetes requiring insulin therapy, as indicated by prescriptions for insulin, than children without congenital anomalies? The aim of this study is to evaluate prescription rates of insulin/insulin analogues in children aged 0–9 years with and without major congenital anomalies. A EUROlinkCAT data linkage cohort study, involving six population-based congenital anomaly registries in five countries. Data on children with major congenital anomalies (60,662) and children without congenital anomalies (1,722,912), the reference group, were linked to prescription records. Birth cohort and gestational age were examined. The mean follow-up for all children was 6.2 years. In children with congenital anomalies aged 0–3 years, 0.04 per 100 child-years (95% CIs 0.01–0.07) had > 1 prescription for insulin/insulin analogues compared with 0.03 (95% CIs 0.01–0.06) in reference children, increasing ten-fold by age 8–9 years. The risk of > 1 prescription for insulin/insulin analogues aged 0–9 years in children with non-chromosomal anomalies (RR 0.92, 95% CI 0.84–1.00) was similar to that of reference children. However, children with chromosomal anomalies (RR 2.37, 95% CI 1.91–2.96), and specifically children with Down syndrome (RR 3.44, 95% CIs 2.70–4.37), Down syndrome with congenital heart defects (RR 3.86, 95% CIs 2.88–5.16) and Down syndrome without congenital heart defects (RR 2.78, 95% CIs 1.82–4.27), had a significantly increased risk of > 1 prescription for insulin/insulin analogues aged 0–9 years compared to reference children. Female children had a reduced risk of > 1 prescription aged 0–9 years compared with male children (RR 0.76, 95% CI 0.64–0.90 for children with congenital anomalies and RR 0.90, 95% CI 0.87–0.93 for reference children). Children without congenital anomalies born preterm (< 37 weeks) were more likely to have > 1 insulin/insulin analogue prescription compared to term births (RR 1.28, 95% CIs 1.20–1.36).Conclusion: This is the first population-based study using a standardised methodology across multiple countries. Males, children without congenital anomalies born preterm and those with chromosomal anomalies had an increased risk of being prescribed insulin/insulin analogues. These results will help clinicians to identify which congenital anomalies are associated with an increased risk of developing diabetes requiring insulin therapy and allow them to reassure families of children who have non-chromosomal anomalies that their risk is similar to that of the general population. What is Known:• Children and young adults with Down syndrome have an increased risk of diabetes requiring insulin therapy.• Children born prematurely have an increased risk of developing diabetes requiring insulin therapy. What is New:• Children with non-chromosomal anomalies do not have an increased risk of developing diabetes requiring insulin therapy compared to children without congenital anomalies.• Female children, with or without major congenital anomalies, are less likely to develop diabetes requiring insulin therapy before the age of 10 compared to male children.
- Open Access
- 24 February 2023
- Published by MDPI AG in International Journal of Environmental Research and Public Health
- Vol. 20 (5) , 4042
Oesophageal Atresia: Prevalence in the Valencian Region (Spain) and Associated Anomalies
The objective was to determine the prevalence of oesophageal atresia (OA) and describe the characteristics of OA cases diagnosed before the first year of life, born between 2007 and 2019, and residents in the Valencian Region (VR), Spain. Live births (LB), stillbirths (SB), and termination of pregnancy for fetal anomaly (TOPFA) diagnosed with OA were selected from the Congenital Anomalies population-based Registry of VR (RPAC-CV). The prevalence of OA per 10,000 births with 95% confidence interval was calculated, and socio-demographic and clinical variables were analyzed. A total of 146 OA cases were identified. The overall prevalence was 2.4/10,000 births, and prevalence by type of pregnancy ending was 2.3 in LB and 0.03 in both SB and TOPFA. A mortality rate of 0.03/1000 LB was observed. A relationship was found between case mortality and birth weight (p-value < 0.05). OA was primarily diagnosed at birth (58.2%) and 71.2% of the cases were associated with another congenital anomaly, mainly congenital heart defects. Significant variations in the prevalence of OA in the VR were detected throughout the study period. In conclusion, a lower prevalence in SB and TOPFA was identified compared to EUROCAT data. As several studies have identified, an association between OA cases and birth weight was found.
- 24 February 2023
- Published by MDPI AG in International Journal of Environmental Research and Public Health
- Vol. 20 (5) , 4042
Open AccessOesophageal Atresia: Prevalence in the Valencian Region (Spain) and Associated Anomalies
The objective was to determine the prevalence of oesophageal atresia (OA) and describe the characteristics of OA cases diagnosed before the first year of life, born between 2007 and 2019, and residents in the Valencian Region (VR), Spain. Live births (LB), stillbirths (SB), and termination of pregnancy for fetal anomaly (TOPFA) diagnosed with OA were selected from the Congenital Anomalies population-based Registry of VR (RPAC-CV). The prevalence of OA per 10,000 births with 95% confidence interval was calculated, and socio-demographic and clinical variables were analyzed. A total of 146 OA cases were identified. The overall prevalence was 2.4/10,000 births, and prevalence by type of pregnancy ending was 2.3 in LB and 0.03 in both SB and TOPFA. A mortality rate of 0.03/1000 LB was observed. A relationship was found between case mortality and birth weight (p-value < 0.05). OA was primarily diagnosed at birth (58.2%) and 71.2% of the cases were associated with another congenital anomaly, mainly congenital heart defects. Significant variations in the prevalence of OA in the VR were detected throughout the study period. In conclusion, a lower prevalence in SB and TOPFA was identified compared to EUROCAT data. As several studies have identified, an association between OA cases and birth weight was found.
- Open Access
- 1 November 2021
- Published by Elsevier in Gaceta Sanitaria
- Vol. 35 (6) , 551-558
Enfermedad de Wilson en España: validación de fuentes utilizadas por los Registros de Enfermedades Raras
- 1 November 2021
- Published by Elsevier in Gaceta Sanitaria
- Vol. 35 (6) , 551-558
Open AccessEnfermedad de Wilson en España: validación de fuentes utilizadas por los Registros de Enfermedades Raras